Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ming-Sound Tsao, MD, FRCPC, William D

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Ming-Sound Tsao, MD, FRCPC, William D"— Presentation transcript:

1 Forty Years of the International Association for Study of Lung Cancer Pathology Committee 
Ming-Sound Tsao, MD, FRCPC, William D. Travis, MD, Elisabeth Brambilla, MD, PhD, Andrew G. Nicholson, MD, FRCPath, Masayuki Noguchi, MD, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 12, Pages (December 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 IASLC contribution to the progress made in pathology of thoracic malignancies during the last 40 years. Upper panel illustrates the milestone in histologic classification of lung cancer and contribution by members of IASLC pathology committee. Lower panel highlights major progress in pathology research during each decade since 1970s. IASLC, International Association for the Study of Lung Cancer; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 World Health Organization Expert Committee on Lung Cancer, Geneva, Switzerland, October 24, 1977: standing (right to left): Raymond Yesner, Chairman (USA); Dr. Wong (WHO); Roger Seal (Wales); WHO Representative; Herbert Spencer, MD (England); Leslie Sobin (WHO), Leiv Kreyberg (Norway); Yukio Shimosato (Japan); P. Mirejovsky (Czechoslovakia); E. Chaves (Brazil); J. Chretien (France); and K. Shanmugaratnam (Singapore). Seated (right to left): Dr. Sobin's secretary; L. G. Olchovskaya (USSR); Mary Matthews (USA); L. Hochholzer (USA); and O. Campobasso (Italy). WHO, World Health Organization. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 World Health Organization Panel for 1999 WHO Classification: left to right: Helmut Popper, Emilio Alvarez Fernandez, Yukio Shimosato, Bryan Corrin, Bruce Mackay, Fred Hirsch, Elisabeth Brambilla, Thomas Colby, William Travis, Samuel Hammar, Philip Hasleton, and Richard Steele. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 2004 World Health Organization Writing Committee, Lyon, March, 2004: left to right: back row: Keith Kerr, Henry Tazelaar, Robert Loire, Alan Burke, David Dail, Elisabeth Brambilla, Allen Gibbs, Francoise Galateau-Salle, Francoise Bijuit-Thivolet, Paul Kleihues, Mojgan Devouassoux-Shisheboran, Michael O. Kurrer, Peter Möller, Bryan Corrin, and Andrew Nicholson; middle row: Victor Roggli, Andrew Churg, Alex Marx, Fabio Menestrina, Masayuki Noguchi, Douglas Flieder, Adi Gazdar, Philip Haseltion, Konrad Muller-Hermelink, and Thomas Colby. Front row: Wilbur Franklin, Leslie Sobin, Yukio Shimosato, Nancy Harris, Tseng-tong Kuo, Philip Cagle, Fred Hirsch, and William Travis. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Pathology Panel meeting for International Association for the Study of Lung Cancer/American Society of Clinical Oncology meeting on Bronchioloalveolar Carcinoma, August 2004 at Armed Forces Institute of Pathology, Washington, DC. Left to right: back row: Wilbur Franklin, Erik Thunnissen, Philip Hasleton, Douglas Henderson, Ming-Sound-Tsao, Kim Geisinger, Douglas Flieder, William Travis, Bruce Johnson, Victor Roggli, and Robert Padera (Pathologist, Brigham & Women's Hospital, Boston, MA); front row: Masayuki Noguchi, Y Minami (Thoracic Pathology Fellow, Tsukuba, Japan), Elisabeth Brambilla, and Ignacio Wistuba, Sanaa Hussein (Thoracic Pathology Fellow, Memorial Sloan Kettering Cancer Center). Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 2011–2013 International Association for the Study of Lung Cancer Pathology Committee discussing classification for the 4th edition of World Health Organization classification during a meeting in Baltimore, MD. From left to right: Iver Peterson, Kim Geisinger, Yasushi Yatabe, Andre Moreira (invitee), Fred R. Hirsch, Alberto Marchevsky (invitee), Masayuki Noguchi, Andrew Nicholson, Lucian Chirieac, Ignacio Wistuba, Yuichi Ishikawa, Ming-Sound Tsao, William Travis, Elisabeth Brambilla, Mary Beth Beasley (invitee), Giuseppe Pelosi (invitee), David Hwang (invitee), Sylvie Lanteujoul (invitee), Kafai To, Mari Mino-Kenudson (invitee), Keith Kerr, Seena Aisner, Erik Thunissen, Victor Roggli, and Kenzo Hiroshima (invitee). Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Ming-Sound Tsao, MD, FRCPC, William D"

Similar presentations

MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE

MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
A RETROSPECTIVE ANALYSIS OF FREQUENCY OF ALK GENE

A RETROSPECTIVE ANALYSIS OF FREQUENCY OF ALK GENE
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.
The 2015 World Health Organization Classification of Lung Tumors

The 2015 World Health Organization Classification of Lung Tumors
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.
E13-01: Insights into thymic epithelial tumor: pathology

E13-01: Insights into thymic epithelial tumor: pathology
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification.
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients.
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Similar presentations

Ads by Google